Escalation With Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials

PLoS ONE - United States
doi 10.1371/journal.pone.0093070
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Phase I Cancer Clinical Trials

British Journal of Cancer
Cancer ResearchOncology
2007English

Escalation Strategies for Combination Therapy Phase I Trials

Pharmaceutical Statistics
StatisticsProbabilityPharmacology
2012English

Time to Progression Ratio in Cancer Patients Enrolled in Early Phase Clinical Trials: Time for New Guidelines?

British Journal of Cancer
Cancer ResearchOncology
2018English

Sequential Designs for Phase I Clinical Trials With Late-Onset Toxicities

Biometrics
StatisticsGeneticsProbabilityMolecular BiologyBiochemistryApplied MathematicsMicrobiology ImmunologyBiological SciencesMedicineAgricultural
2000English

A New Pragmatic Design for Dose Escalation in Phase 1 Clinical Trials Using an Adaptive Continual Reassessment Method

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Phase I Trials as Valid Therapeutic Options for Patients With Cancer

Nature Reviews Clinical Oncology
Oncology
2019English

Toxicity of Phase I Radiation Oncology Trials: Worldwide Experience

2010English

A Novel Toxicity Scoring System Treating Toxicity Response as a Quasi-Continuous Variable in Phase I Clinical Trials

Contemporary Clinical Trials
MedicinePharmacology
2010English

A Dynamic Stopping Rule for Phase I Clinical Trials

Biometrical Letters
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy